Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of…
<!-- Name:DistributionId Value:8754713 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
CROI
Theratechnologies présente de nouvelles données sur la tésamoréline démontrant une…
<!-- Name:DistributionId Value:8754713 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Third ‘Cured’ HIV Patient Headlines CROI 2022
An oral abstract presented at the virtual Conference on Retroviruses and Opportunistic Infections (CROI)…
Long-Acting Prevention and Treatment of HIV: CROI 2022 Part 2
At the virtual Conference on Retroviruses and Opportunistic Infections (CROI), researchers presented multiple…
Long-Acting Prevention and Treatment of HIV: CROI 2022 Update
At the virtual Conference on Retroviruses and Opportunistic Infections (CROI), researchers presented multiple…
Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at…
No difference in pharmacokinetics between IV Push and IV InfusionNo serious adverse events observedNo difference in viral load between IV Push and IV Infusion and no anti-drug antibodies…